Compare GOSS & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOSS | THW |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 145 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 513.9M |
| IPO Year | 2018 | 2015 |
| Metric | GOSS | THW |
|---|---|---|
| Price | $0.44 | $12.08 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $4.91 | N/A |
| AVG Volume (30 Days) | ★ 26.7M | 136.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $114,701,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $9.80 |
| 52 Week High | $3.87 | $13.19 |
| Indicator | GOSS | THW |
|---|---|---|
| Relative Strength Index (RSI) | 22.21 | 38.81 |
| Support Level | $0.33 | $11.80 |
| Resistance Level | $0.60 | $12.13 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 45.47 | 24.73 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.